Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.44 |
| ▸ | C1S | P09871 | 4/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30214020 | 0.89 | ERN1 (0.41) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29560021 | 0.83 | KDM4E (0.43) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10084142 | 0.75 | KDM4E (0.38) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31322056 | 0.75 | KDM4E (0.38) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2953851 | 0.75 | IMPDH2 (0.44) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2952488 | 0.75 | KDM4E (0.47) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2951372 | 0.75 | IMPDH2 (0.44) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| Formic Acid SCHEMBL30994748 | 0.74 | ERN1 (0.38) | LMNACYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29560277 | 0.74 | KDM4E (0.57) | LMNACYP1A2CYP3A4CYP2D6C1S | |
| SCHEMBL600018 | 0.74 | KDM4E (0.57) | LMNACYP1A2CYP3A4CYP2D6C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-05-16 | — | — | US | claimed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12410167-B2 | Pyridazine compounds for inhibiting NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250250270-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250236620-A1 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | VENTUS THERAPEUTICS U S INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12351578-B2 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12312350-B2 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230303559-A1 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES | VENTUS THERAPEUTICS U.S., INC. | 2023-09-28 | — | — | US | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220340567-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | VENTUS THERAPEUTICS U.S., INC. (US) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340567-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
| US-20230159526-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
| US-12410167-B2 | Pyridazine compounds for inhibiting NLRP3 | NLRP3, NLRP1, NOD1 | LMNA 1410/4885CYP1A2 4080/4885CYP3A4 4409/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | LMNA 3751/4885CYP1A2 4781/4885CYP3A4 4860/4885 |
| US-12312350-B2 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | NLRP3, NLRP1, PYCARD | LMNA 761/4885CYP1A2 2960/4885CYP3A4 1650/4885 |
| US-20250236620-A1 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NLRP1, PYCARD | LMNA 1008/4885CYP1A2 3094/4885CYP3A4 3056/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | LMNA 3751/4885CYP1A2 4781/4885CYP3A4 4860/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | LMNA 3751/4885CYP1A2 4781/4885CYP3A4 4860/4885 |
| US-20230303559-A1 | PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES | NLRP3, NLRP1, PYCARD | LMNA 1002/4885CYP1A2 3170/4885CYP3A4 3220/4885 |
| US-20250250270-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | LMNA 3902/4885CYP1A2 4753/4885CYP3A4 4856/4885 |
| US-11319319-B1 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
| US-12351578-B2 | Compounds for inhibiting NLRP3 and uses thereof | NLRP3, NLRP1, PYCARD | LMNA 945/4885CYP1A2 3888/4885CYP3A4 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.